0001209191-19-049105.txt : 20190910 0001209191-19-049105.hdr.sgml : 20190910 20190910210535 ACCESSION NUMBER: 0001209191-19-049105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190909 FILED AS OF DATE: 20190910 DATE AS OF CHANGE: 20190910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aurentz Vincent CENTRAL INDEX KEY: 0001657494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 191087029 BUSINESS ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 453-7200 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Vincent Aurentz DATE OF NAME CHANGE: 20151103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-09 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001657494 Aurentz Vincent C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 Executive VP and CBO Common Stock 2019-09-09 4 M 0 25000 17.10 A 25000 D Common Stock 2019-09-09 4 M 0 10000 14.60 A 35000 D Common Stock 2019-09-09 4 M 0 30000 35.60 A 65000 D Common Stock 2019-09-09 4 S 0 44672 50.4835 D 20328 D Common Stock 2019-09-09 4 S 0 20328 51.2348 D 0 D Employee Stock Option (right to buy) 17.10 2019-09-09 4 M 0 25000 0.00 D 2023-08-15 Common Stock 25000 55000 D Employee Stock Option (right to buy) 14.60 2019-09-09 4 M 0 10000 0.00 D 2024-02-13 Common Stock 10000 89500 D Employee Stock Option (right to buy) 35.60 2019-09-09 4 M 0 30000 0.00 D 2025-01-19 Common Stock 30000 100000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2 and 3 to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.54, inclusive. The options vest over four years and are exercisable once vested. 25% vested and became exercisable on August 15, 2017. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on September 15, 2017, and the thirty-sixth installment vesting on August 15, 2020. The options vest over four years and are exercisable once vested. 25% vested and became exercisable on February 13, 2018. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on March 13, 2018, and the thirty-sixth installment vesting on February 13, 2021. The options vest over four years and are exercisable once vested. 25% vested and became exercisable on January 19, 2019. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on February 19, 2019, and the thirty-sixth installment vesting on January 19, 2022. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2019-09-10